Immunovant, Inc.

Overview

Compare with another stock.

• TickerIMVT on Nasdaq¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersDurham, North Carolina¹
• Incorporated inDE³
• Business address1000 Park Forty Plaza, Durham, Nc 27713³
• Filer categoryLarge accelerated filer³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.⁴ From its latest annual report

Corporate structure

Immunovant, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Immunovant, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We conduct business operations at 1000 Park Forty Plaza, Suite 210, Durham, North Carolina 27713. ISL’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda and ISL’s principal office is located at 7th Floor, 50 Broadway, London, SW1H 0DB. ISG conducts business operations at Viaduktstrasse 8, 4051 Basel, Switzerland.

We could add new facilities or expand our existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

Item 2 of the 10-K filed May 20, 2026.⁴

Leadership

Who has led Immunovant, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerEric Venker Jul 30, 2025 to now¹⁴
• Chief executive officerRoderick Wong May 9, 2019 to Dec 13, 2019¹⁵
• Chief executive officerPeter Salzmann Dec 20, 2019 to Jul 30, 2025¹⁶
• PresidentRoderick Wong May 9, 2019 to May 9, 2019¹⁵
• Chief financial officerTiago Girao Apr 28, 2025 to now¹⁷
• Chief financial officerEva Renee Barnett Oct 5, 2021 to Apr 28, 2025¹⁸
• Chief financial officerNaveen Yalamanchi May 9, 2019 to May 9, 2019¹⁹
• Chief financial officerConnealy Pamela Yanchik Dec 20, 2019 to Mar 23, 2021²⁰
• Chief operating officerMelanie Gloria Nov 20, 2024 to now²¹

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerChristopher Van Tuyl named Jan 21, 2025⁴⁵

Former names

• Health Sciences Acquisitions CorpJan 23, 2019 to Dec 20, 2019³

Timeline

1. Sep 3, 20268-K Shareholder vote⁴⁶
2. Aug 6, 20268-K Results of operations⁴⁷
3. May 20, 20268-K Results of operations⁴⁸
4. Feb 6, 20268-K Results of operations⁴⁹
5. Dec 12, 20258-K Other events⁵⁰
6. Dec 11, 20258-K Other events⁵¹
7. Nov 21, 20258-K Executive or director change⁵²
8. Nov 10, 20258-K Results of operations⁵³
9. Sep 3, 20258-K Regulation FD disclosure; Other events⁵⁴
10. Aug 28, 20258-K Shareholder vote⁵⁵
11. Aug 11, 20258-K Results of operations⁵⁶
12. Jul 30, 2025New chief executive Eric Venker becomes CEO¹⁴
13. Jul 29, 20258-K Executive or director change⁵⁷
14. Dec 20, 2019New chief executive Peter Salzmann becomes CEO¹⁶
15. May 9, 2019New chief executive Roderick Wong becomes CEO¹⁵

Calendar

Coming up

1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.73) a share, on Nov 10, 2025.⁵⁸

When it reported results

1. Aug 6, 2026Reported quarterly or annual results⁴⁷
2. May 20, 2026Reported quarterly or annual results⁴⁸
3. Feb 6, 2026Reported quarterly or annual results⁴⁹
4. Nov 10, 2025Reported quarterly or annual results⁵³
5. Aug 11, 2025Reported quarterly or annual results⁵⁶
6. May 29, 2025Reported quarterly or annual results⁵⁹
7. Feb 6, 2025Reported quarterly or annual results⁶⁰
8. Nov 7, 2024Reported quarterly or annual results⁶¹

Drug trials and FDA: coming up

1. Oct 2026Phase 2 trial readout expected Phase 2 trial of IMVT-1402 in Subacute Cutaneous Lupus Erythematosus: primary completion expected Oct 2026 (ClinicalTrials.gov NCT06980805).⁶²
2. May 2027Phase 2 trial readout expected Phase 2 trial of IMVT-1402 in Graves' Disease: primary completion expected May 2027 (ClinicalTrials.gov NCT07018323).⁶³
3. Sep 2027Phase 2 trial readout expected Phase 2 trial of IMVT-1402 in Rheumatoid Arthritis: primary completion expected Sep 2027 (ClinicalTrials.gov NCT06754462).⁶⁴

Drug trials and FDA: recently

1. Feb 3, 2026Phase 3 trial completed Phase 3 trial of Batoclimab in Thyroid Eye Disease: primary completion Feb 3, 2026, no results posted yet (ClinicalTrials.gov NCT05524571).⁶⁵
2. Nov 2, 2025Phase 3 trial completed Phase 3 trial of Batoclimab in Thyroid Eye Disease: primary completion Nov 2, 2025, no results posted yet (ClinicalTrials.gov NCT05517421).⁶⁶
3. Jul 25, 2025Phase 2 trial completed Phase 2 trial of IMVT-1401 (batoclimab) in Graves Disease: primary completion Jul 25, 2025, results posted Aug 13, 2026 (ClinicalTrials.gov NCT05907668).⁶⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

415 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 269 insider forms, 15 large holders, 1 private raises, 57 other. The latest 20:

1. Oct 9, 20264 EDGAR
2. Oct 9, 20264 EDGAR
3. Oct 9, 20264 EDGAR
4. Oct 5, 20264 EDGAR
5. Sep 25, 20264 EDGAR
6. Sep 3, 20268-K EDGAR
7. Aug 28, 20264 EDGAR
8. Aug 21, 20264 EDGAR
9. Aug 14, 2026SCHEDULE 13G/A EDGAR
10. Aug 6, 202610-Q EDGAR
11. Aug 6, 20268-K EDGAR
12. Jul 24, 20264 EDGAR
13. Jul 24, 20264 EDGAR
14. Jul 24, 20264 EDGAR
15. Jul 22, 2026ARS EDGAR
16. Jul 22, 2026DEFA14A EDGAR
17. Jul 22, 2026DEF 14A EDGAR
18. Jul 10, 20264 EDGAR
19. Jul 10, 20264 EDGAR
20. Jul 10, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

186 open-market trades by officers, directors and large owners since October 2021: 6 buys and 180 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Deep Track Capital, LPSCHEDULE 13G/A, 5 filings Feb 11, 2022 to Aug 14, 2026⁶⁸
• RoivantSCHEDULE 13D/A, 4 filings Oct 4, 2023 to Dec 12, 2025⁶⁹
• FMR LLCSCHEDULE 13G/A, 4 filings Feb 9, 2024 to Nov 5, 2025⁷⁰
• RTW INVESTMENTS, LPSC 13G/A, 2 filings Dec 2, 2022 to Dec 5, 2022⁷¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jan 15, 2025Raised $450 million in a private offering of equity⁴⁵ Form D: 11 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Immunovant, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARImmunovant, Inc.¹
• CIK0001764013
• Employer ID (EIN)83-2771572⁴
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsMarch 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address1000 Park Forty Plaza, Durham, NC 27713¹
• Phone917-410-3120¹
• Shares outstanding206,552,682 as of Aug 3, 2026¹²
• Public float$1.3B as of Sep 30, 2025⁴
• AuditorErnst & Young LLP, Iselin, New Jersey PCAOB ID 42; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceJan 23, 2019¹
• Filings646 in all: 4 (322), 8-K (84), 3 (34), 144 (26), 10-Q (23), DEFA14A (16), CORRESP (13), UPLOAD (12)¹
  All 46 form types

  SC 13G/A (11), S-8 (8), 10-K (7), 424B3 (7), DEF 14A (7), SC 13D/A (7), SC 13G (6), 424B5 (5), EFFECT (5), S-1/A (5), S-1 (4), 424B4 (3), ARS (3), DRS (3), FWP (3), SCHEDULE 13D/A (3), SCHEDULE 13G/A (3), POS EX (2), PRER14A (2), S-1MEF (2), SC 13D (2), SEC STAFF LETTER (2), 25-NSE (1), 4/A (1), 424B7 (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), DEFM14A (1), DEFR14A (1), DRS/A (1), DRSLTR (1), PRE 14A (1), PREM14A (1), S-3 (1), S-3ASR (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) May 20, 2026
  Quarterly report (10-Q) Aug 6, 2026
  Proxy statement (DEF 14A) Jul 22, 2026
  Latest 8-K (8-K) Sep 3, 2026

Securities registered for trading

From the cover page of the 10-K filed May 20, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Immunovant, Inc. names in Item 1A of its 10-K filed May 20, 2026: 76 risks under these headings, as written.⁴

• Risks Related to Development, Regulatory Approval and Commercialization
• Our business is dependent on the successful and timely development, regulatory approval and commercialization of our product candidates.
• Clinical trials are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control and we may not be able to enroll patients in our trials on our anticipated timelines.
• The results of our preclinical studies and clinical trials may not support our proposed claims for our product candidates, or regulatory approval on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results.
• Interim, “top-line” or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Our product candidates may be associated with adverse events or cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, cause us to abandon further development or limit the commercial viability of any approved label or market acceptance.
• Our product candidates are antibody proteins that could cause an immune response in patients, resulting in the creation of harmful or neutralizing antibodies against these therapeutic proteins, preventing or limiting regulatory approval or our ability to commercialize our product candidates.
• If we are not able to obtain required regulatory approvals, we will not be able to commercialize IMVT-1402 or any future product candidate, and our ability to generate product revenue will be impaired.
• We have in-licensed the rights to IMVT-1402 and batoclimab in limited territories. Any adverse developments that occur during any clinical trials or manufacturing conducted by third parties, including HanAll, in other jurisdictions may affect our ability to obtain regulatory approval or commercialize our product candidates.
• We face significant competition from other biotechnology and pharmaceutical companies targeting autoimmune disease indications. Our operating results will suffer if we fail to compete effectively.
• Additional time may be required to obtain marketing authorizations for the autoinjector presentation of IMVT-1402 because it would be subject to regulation as a combination product.

Legal proceedings

From time to time, we have been and may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash flows.

For a description of our legal proceedings, see Part II, Item 8. Financial Statements and Supplementary Data, Note 10 – Commitments and Contingencies for more information.

The opening of Item 3, Legal Proceedings.⁴